Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wieler, M.
Right arrow Articles by Wayne Martin, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wieler, M.
Right arrow Articles by Wayne Martin, W. R.
Related Collections
Right arrow Parkinson's disease/Parkinsonism
Right arrow Botulinum toxin
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2005;65:626-628
© 2005 American Academy of Neurology
Brief Communications

Botulinum toxin injections do not improve freezing of gait in Parkinson disease

Marguerite Wieler, MSc, Richard Camicioli, MD, C. Allyson Jones, PhD and W. R. Wayne Martin, MD

From the Departments of Medicine (Neurology) (Drs. Camicioli and Martin, M. Wieler) and Physical Therapy and Public Health Science (Dr. Jones), University of Alberta, Edmonton, Canada.

Address correspondence and reprint requests to M. Wieler, Movement Disorders Clinic, Glenrose Rehabilitation Hospital, 10230 111 Ave., Edmonton, AB, Canada T5G 0B7; e-mail: marguerite.wieler{at}ualberta.ca

Freezing of gait (FOG) is common in patients with Parkinson disease (PD) and responds poorly to medical treatment. Botulinum toxin A (BTX-A) injections into calf muscles decreased FOG in previous open-label studies. The authors conducted a randomized double-blind placebo-controlled crossover study of BTX-A vs placebo in 12 subjects with PD and FOG. No significant improvement with BTX-A was found using subjective and objective measures.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the August 23 issue to find the title link for this article.

Funded by a grant from the Parkinson Society Canada. The botulinum toxin was provided, free of charge, by Allergan.

Disclosure: The authors report no conflicts of interest.

Received November 19, 2004. Accepted in final form May 13, 2005.




This article has been cited by other articles:


Home page
 NeurologyHome page
C. W. Olanow, M. B. Stern, and K. Sethi
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Neurology, May 26, 2009; 72(21_Supplement_4): S1 - S136.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.